Literature DB >> 9678624

Malignant mixed müllerian tumor of the uterus. Features favoring its origin from a common cell clone and an epithelial-to-mesenchymal transformation mechanism of histogenesis.

M Guarino1, F Giordano, F Pallotti, G Polizzotti, P Tricomi, E Cristofori.   

Abstract

AIMS AND
BACKGROUND: Various histogenetic mechanisms have been postulated to explain the biphasic carcinomatous-sarcomatous appearance of malignant mixed mullerian tumors (MMMTs), but the nature of these uncommon neoplasms is still unclear. Some evidence would suggest that MMMT displays similarities with sarcomatoid carcinoma, a tumor arising in extragenital sites that also features a mixed appearance. To gain further insight into the histogenesis of this tumor, we have studied by immunohistochemistry a case of uterine MMMT showing an extensive rhabdomyosarcomatous component.
METHODS: A panel of antibodies including reactivity for p53, cytokeratin, vimentin, desmin, muscle actin, epithelial membrane antigen (EMA), myoglobin, type IV collagen, laminin, and tenascin was applied to paraffin tumor sections by means of the avidin-biotin complex technique.
RESULTS: p53 immunoreactivity was observed in approximately the same number of cells in carcinomatous and sarcomatous tissue. The former stained for vimentin, cytokeratin and EMA, while the latter, in addition to expressing vimentin, desmin, muscle actin and myoglobin, also exhibited immunoreactivity for epithelial markers such as cytokeratin and EMA. At the borders between carcinoma and sarcoma the basement membrane pattern, as seen by staining for type IV collagen and laminin, showed interruptions in correspondence with areas of transition between the two tissues. Antibody to tenascin strongly labeled the sarcomatous tissue immediately around carcinomatous elements.
CONCLUSIONS: A similar immunoreactivity for p53 in both carcinomatous and sarcomatous components, expression of epithelial markers in the sarcomatous cells, and disruption of the basement membrane profile in areas of transition between carcinomatous and sarcomatous tissue, would all suggest, as has been postulated for extragenital sarcomatoid carcinomas, an origin from a common epithelial clone and an epithelial-to-mesenchymal transformation-based mechanism of development for this MMMT. In addition, these findings provide further analogies between these categories of tumors, supporting a unifying nosological concept for MMMTs and sarcomatoid carcinomas of non-genital tract origin.

Entities:  

Mesh:

Year:  1998        PMID: 9678624     DOI: 10.1177/030089169808400316

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  5 in total

1.  Mesenchymal Stem Cells: Miraculous Healers or Dormant Killers?

Authors:  Abbas Ghaderi; Shabnam Abtahi
Journal:  Stem Cell Rev Rep       Date:  2018-10       Impact factor: 5.739

Review 2.  Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Authors:  T S Shylasree; Andrew Bryant; Ram Athavale
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

3.  miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.

Authors:  Jill H Tseng; Maria Bisogna; Lien N Hoang; Narciso Olvera; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; Douglas A Levine; Petar Jelinic
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

4.  Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.

Authors:  Hyun Ju Lee; Jong Jin Lee; Jeong Yeol Park; Jong Hyeok Kim; Yong Man Kim; Young Tak Kim; Joo Hyun Nam
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

5.  Epithelial cell migration requires the interaction between the vimentin and keratin intermediate filaments.

Authors:  Cristina Velez-delValle; Meytha Marsch-Moreno; Federico Castro-Muñozledo; Ivan J Galván-Mendoza; Walid Kuri-Harcuch
Journal:  Sci Rep       Date:  2016-04-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.